

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

### ***APPLICATION NUMBER:***

**214869Orig1s000**

***Trade Name:*** Dhivy tablet

***Generic or Proper Name:*** carbidopa 25 mg/levodopa 100 mg

***Sponsor:*** Riverside Pharmaceuticals Corporation

***Approval Date:*** November 12, 2021

***Indication:*** For the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 214869Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Clinical Review(s)</b>	<b>X</b>
<b>Product Quality Review(s)</b>	<b>X</b>
<b>Non-Clinical Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	
<b>Clinical Microbiology / Virology Review(s)</b>	
<b>Clinical Pharmacology Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**214869Orig1s000**

**APPROVAL LETTER**

NDA 214869

**NDA APPROVAL**

Riverside Pharmaceuticals Corporation  
Attention: Thomas N. Chase, SB, MD  
Chief Executive Officer  
1825 K Street NW, Suite 520  
Washington, DC 20006

Dear Dr. Chase:

Please refer to your new drug application (NDA) dated October 14, 2020, received October 14, 2020, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dhivy (carbidopa 25 mg/ levodopa 100 mg) tablet.

We acknowledge receipt of your major amendment dated July 30, 2021, which extended the goal date by three months.

This NDA provides for the use of Dhivy (carbidopa 25 mg/ levodopa 100 mg) tablet for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed container labeling that is identical to the container labeling submitted on June 22, 2021, as soon as it is available, but no more than 30 days after it is printed. Please submit this label electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Container Labeling for approved NDA 214869.**” Approval of this submission by FDA is not required before the labeling is used.

### **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Dhivig (carbidopa 25 mg/ levodopa 100 mg) tablet shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication,

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>4</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>5</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Stacy Metz, PharmD, Senior Regulatory Project Manager, at [stacy.metz@fda.hhs.gov](mailto:stacy.metz@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Teresa Buracchio, MD  
Director (Acting)  
Division of Neurology 1  
Office of Neuroscience  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

---

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TERESA J BURACCHIO  
11/12/2021 12:27:42 PM